-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Guangxiang Pharmaceutical of Shijiazhuang Sihua Pharmaceutical Group Obtains Cangzhou City’s First “Carbon Certificate”
Category:
发布时间：2024-03-15
【概要描述】
On March 13, Cangzhou City held a certificate-awarding ceremony for the carbon footprint report at Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, presenting the city’s first carbon footprint report certification to Guangxiang Pharmaceutical. This milestone underscores the company’s significant achievements in advancing the “dual carbon” goals and realizing green development.
On March 13, Cangzhou City held a certificate-awarding ceremony for the carbon footprint report at Hebei Guangxiang Pharmaceutical Co., Ltd., part of Shijiazhuang Sihua Pharmaceutical Group, presenting the city’s first carbon footprint report certification to Guangxiang Pharmaceutical. This milestone underscores the company’s significant achievements in advancing the “dual carbon” goals and realizing green development.
“The product carbon footprint is a form of carbon-emissions accounting that generally refers to the total carbon emissions generated throughout a product’s lifecycle—from raw-material processing and transportation to manufacturing and final sale. It serves as an important indicator for assessing the green and low-carbon performance of manufacturing enterprises and their products.” Liu Yong, a member of the Standing Committee of the CPC Cangzhou Municipal Committee and Executive Vice Mayor of Cangzhou, explained that establishing a product carbon-footprint management system and implementing authoritative carbon-footprint reporting and certification are crucial measures for proactively addressing green trade barriers, safeguarding domestic interests, and enhancing core competitiveness in international markets. By providing clear and transparent data on product carbon emissions, these initiatives can encourage greater public preference for low-carbon products, channel consumer demand for green and low-carbon goods back to the production side, boost product competitiveness, and strengthen the green and low-carbon brand value of enterprises.
“The attainment of the first carbon footprint report certification is the result of our sustained efforts to conserve energy and reduce emissions. We have invested in high-efficiency equipment to lower energy consumption and implemented measures such as recycling process water, steam condensate, and waste heat from our systems, thereby achieving closed-loop utilization of thermal and water resources. In addition, we employ membrane separation technology to treat high-salinity wastewater; the clarified effluent after membrane treatment can be directly subjected to biochemical treatment, significantly reducing our carbon footprint,” said Cui Yongbin, Chairman of Guangxiang Pharmaceutical. He added that going forward, the company will formulate more proactive and effective emission-reduction measures in accordance with the requirements of the product carbon footprint management system, optimize production processes, and continue to lower its carbon emissions.
In recent years, Guangxiang Pharmaceutical, a subsidiary of the Group, has been driven by innovation and seized the strategic opportunities presented by the Beijing–Tianjin–Hebei coordinated development initiative. The company has integrated the concept of green development throughout its entire production and business operations, actively upgrading the green manufacturing standards for active pharmaceutical ingredients. By delivering high-quality supply that both creates and leads demand, Guangxiang Pharmaceutical has continuously strengthened the appeal of its products in both domestic and international markets, thereby steadily enhancing its overall competitiveness. In 2023, Guangxiang Pharmaceutical was recognized as a “Green Factory” by the Ministry of Industry and Information Technology. Currently, the Group boasts 50 API product varieties, with Guangxiang Pharmaceutical accounting for 30 of them, resulting in an increasingly diversified product portfolio and accelerating progress in the internationalization of its operations. Notably, the company’s production capacity for caffeine, a bulk API, ranks among the industry’s highest, earning widespread acclaim in both domestic and global markets.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091